KPC Pharmaceuticals, Inc. Class A

KPC Pharmaceuticals, Inc. Class A

SSSE:600422
8.47
CNY
0.00
(0.00%)
-0.36EPS
6.14BMarket Cap
Mar 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.51
5.47
6.23
6.47
7.45
9.24
10.66
10.17
10.89
11.02
11.07
11.15
8.64
6.03
Basic EPS, GAAP
0.36
0.37
0.53
0.52
0.42
0.44
0.6
0.6
0.67
0.51
0.71
0.86
0.46
-0.38
Free Cash Flow per Basic Share
0.05
0.22
0.34
0.14
0.02
0.18
0.11
0.33
0.02
0.2
0.85
0.97
0.26
- -
Dividend per Share
0.16
0.18
0.09
0.23
0.21
0.06
0.15
0.24
0.27
0.31
0.19
0.23
0.37
0.24
Book Value per Share
2.58
3.13
4.2
4.51
4.65
5.01
5.51
5.87
6.31
6.57
8.66
6.94
7.08
6.42
Tangible Book Value per Share
2.17
2.59
3.69
3.85
3.83
4.12
4.57
5
5.38
5.75
5.81
4.12
4.27
3.61
Basic Weighted Avg Shares
651
789
789
789
786
769
761
759
758
751
762
754
761
754
Sales/Revenue/Turnover
3,584
4,316
4,916
5,101
5,852
7,102
8,120
7,717
8,254
8,282
8,430
8,401
6,575
4,546
Operating Margin (%)
8.09
7.9
9.84
7.97
7.54
6.09
6.89
7.06
6.98
7.42
10.56
11.74
5.71
-3.83
Depreciation Expense
45
70
77
81
95
100
124
151
184
209
209
199
193
- -
Net Income, GAAP
232
289
421
407
330
336
454
457
508
383
541
648
350
-285
Effective Tax Rate (%)
16.92
16.65
14.75
14.85
17.81
18.09
14.08
14.49
18.7
19.24
18.27
19.62
11.51
- -
Profit Margin (%)
6.46
6.69
8.56
7.98
5.64
4.72
5.59
5.92
6.15
4.63
6.41
7.71
5.32
-6.28
Working Capital
1,102
1,046
1,837
2,008
2,018
2,035
2,024
2,411
2,695
2,878
4,283
3,064
3,898
3,446
LT Debt
- -
- -
298
298
339
255
67
168
150
105
152
95
737
708
Total Equity
1,879
2,271
3,336
3,612
3,774
3,949
4,334
4,603
4,940
5,143
7,954
6,746
6,941
6,444
Return on Invested Capital (%)
14.43
12.98
12.76
9.23
7.97
7.54
9.67
8.96
9.25
6.71
8.58
9.12
4.97
- -
Return on Capital (%)
15.11
12.66
13.53
10.71
8.11
8.02
9.93
9.2
9.46
6.87
6.03
6.89
4.02
- -
Return on Common Equity (%)
17.18
14.83
15.45
11.86
9.14
8.96
11.33
10.57
11
7.85
9.37
10.97
6.59
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
874
908
770
LT Borrowings
693
690
677
LT Finance Leases
48
37
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
757
757
757
Market Capitalization
8,630
5,912
6,139

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
7,124
6,920
6,559
Cash, Cash Equivalents & STI
1,624
1,711
1,372
Accounts Receivable, Net
3,377
3,043
3,182
Inventories
1,513
1,551
1,404
Total Current Liabilities
3,412
3,553
3,113
Payables & Accruals
- -
- -
- -
ST Debt
874
908
770
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.72%
10.76%
2.89%
Free Cash Flow
194%
210.92%
-72.73%
Net Income, GAAP
1.7%
0.31%
-46%
Sales/Revenue/Turnover
3.62%
-2.6%
-21.74%
Total Cash Common Dividend
34.4%
13.93%
62.31%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,927
1,702
1,903
2,944
8,401
2025
1,608
1,743
- -
1,824
6,575
2026
836
807
1,079
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.15
0.21
0.34
0.86
2025
0.12
0.14
- -
0.11
0.46
2026
-0.19
-0.29
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.21
0.01
0.23
2025
0.01
0.02
- -
0.03
0.37
2026
0.01
0.01
0.19
- -
- -

Company Description

CEO
Wei Yan
Full Time Employees
5,072
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.166 Keyi Road Kunming YU China 650106
IPO Date
Dec 6, 2000
Website
kpc.com.cn
Business
KPC Pharmaceuticals, Inc., a prominent drug manufacturer, is actively engaged in the research, development, production, and widespread distribution of pharmaceutical products within the People's Republic of China and across international markets. The company specializes in innovative natural botanical medicines, traditional Chinese remedies, and chemical pharmaceuticals, encompassing a broad range of drug circulation activities. Its comprehensive product portfolio features the Artemether series, crucial for malaria treatment, alongside the Panax Notoginseng and Gastrodine series, primarily targeting cardio-cerebral-vascular and nervous system disorders. Brands such as Luotai, Tianxuanqing, Artemedine, Artem, and Arco are well-regarded both domestically and internationally. Beyond these core offerings, KPC Pharmaceuticals also provides ethnic medicines, various antibiotics, essential chemical pharmaceutical raw materials, finished chemical preparations, traditional Chinese medicinal ingredients, biological agents, biochemical drugs, and health food items. The company’s strategic focus extends to chronic disease management and the burgeoning "silver age" health industry, leveraging Yunnan's rich plant resources to develop over 40 natural botanical drugs. Notably, its "777" brand centers on the Panax notoginseng series, and it holds a significant market share in Gastrodin products with the Tianxuanqing brand. KPC also champions artemisinin antimalarials globally, particularly in Africa, overseeing the entire value chain from cultivation to distribution. The enterprise, which originated as Kunming Pharmaceutical Corporation and adopted its current name in April 2015, was established in 1951 and maintains its headquarters in Kunming, China. It was listed on the Shanghai Stock Exchange in 2000 and currently operates numerous subsidiaries, distributing products in over 60 countries.